BEAT — Heartbeam, Inc.
Is BEAT overbought or oversold? Here is the current MarketMoodz read.
Heartbeam, Inc. (BEAT) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Health Information Services) last closed at $0.36. The rating moved from Oversold to Strong Oversold on November 14, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$0.36
- Last changeMoved from Oversold to Strong Oversold on November 14, 2026
- SectorHealthcare
- IndustryHealth Information Services
See all oversold Healthcare stocks →
AI analysis
Heartbeam, Inc. (BEAT) is a microcap healthcare issuer with limited public financial disclosure and low liquidity. Near‑term fundamentals are constrained by uncertain revenue, a likely need for external financing, and clinical/regulatory execution requirements. Sector tailwinds toward at‑home monitoring and outpatient care provide possible pathways to commercialization if clinical validation or strategic partnerships materialize, but competition, reimbursement complexity, and dilution risk dominate the near-term outlook. Absent clear near‑term milestones or improved financial transparency, price movements are likely to be driven by episodic news and funding events rather than steady operational progress.
Key factors
- Very low market capitalization and thin liquidity increase volatility and limit institutional interest
- Limited publicly available recent EDGAR/filings and unclear near‑term revenue visibility
- Technology/clinical-stage profile with potential upside if clinical validation, regulatory clearance, or commercial partnerships occur
- Healthcare sector themes (shift to outpatient/at‑home monitoring and payer interest in value-based tools) provide a constructive backdrop for cardiac-monitoring solutions
- Macro risk-on sentiment and growth-sector flows may temporarily lift microcap healthcare stocks, but benefits are uneven
- Convertible-debt and broader financing environment in diagnostics/biotech suggest higher dilution risk for small issuers
Risks
- High likelihood of equity dilution from financings or convertible instruments that would depress existing share value
- Regulatory or clinical setbacks that delay product commercialization or reimbursement timelines
- Intense competition from established device and digital-health players with deeper distribution and payer relationships
- Limited operating cash and uncertain near-term revenue, raising cash‑runway concerns
- Low trading liquidity causing wide spreads and outsized moves on limited news or block trades
- Reimbursement hurdles and slow Medicare/insurer adoption that reduce commercial scale
- Lack of social/media/research coverage limits retail momentum and secondary funding access
- Sector/market rotations away from small-cap healthcare names could accelerate declines in adverse macro conditions
See today's live rating, score and targets
Members see the live hourly rating for BEAT — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.